ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

UNC Oncologist Edison Liu To Direct NCI Intramural Clinical Research Programs

June 28, 1996

Grassley, House Republicans Launch Investigations Of I-ELCAP Conflicts.

June 6, 2008

NIH Review Process A Disaster, Borek Says

October 19, 1979

Amgen Announces Cochrane Findings: ESAs Increase Risk Of On-Study Death.

October 3, 2008

DCT Board Approves Concept To Recomplete Data Management Contract

June 29, 1984

Long-Term Results Of STAR Find Raloxifene Causes Fewer, Less Severe Side Effects

April 30, 2010